Ho-dac-Pannekeet M M, Schouten N, Langendijk M J, Hiralall J K, de Waart D R, Struijk D G, Krediet R T
Department of Nephrology, Academic Medical Center, Amsterdam, The Netherlands.
Kidney Int. 1996 Sep;50(3):979-86. doi: 10.1038/ki.1996.399.
Dialysate fluids containing glucose polymers as osmotic agent are different from the conventional solutions, because they are iso-osmotic to plasma and produce transcapillary ultrafiltration (TCUF) by colloid osmosis. To investigate the effects on fluid and solute kinetics, a comparison was made between a 7.5% glucose polymer based dialysate (icodextrin) and 1.36% and 3.86% glucose based dialysate in 10 stable CAPD patients. In each patient three standard peritoneal permeability analyses (SPA) were done with the osmotic agents and concentrations mentioned above. Dextran 70 was added to the glucose solutions to calculate fluid kinetics. In the glucose polymer SPAs fluid kinetics were calculated from the dilution and disappearance of dextrin. The TCUF rate with icodextrin was closer to that obtained with 3.86% glucose than to 1.36% glucose. Extrapolation of the fluid profiles revealed sustained ultrafiltration with icodextrin. TCUF increased linearly in time in the icodextrin tests, whereas a hyperbola best described the glucose profiles. The effective lymphatic absorption rate with icodextrin was similar to the glucose based solutions. Mass transfer area coefficients of low molecular weight solutes with icodextrin were also similar to the values obtained with glucose, as was D/P creatinine. A positive correlation was present between the MTAC creatinine and the TCUF rate with icodextrin (r = 0.66, P = 0.05), which was absent in the glucose SPAs. This suggests that in patients with a larger effective peritoneal surface area, more ultrafiltration can be achieved by glucose polymer solutions. Clearances of beta 2-microglobulin (beta 2m) were higher with icodextrin than with 3.86% glucose and 1.36% glucose dialysate (P < 0.05). No differences were found for the larger serum proteins albumin, IgG and alpha 2-macroglobulin. Initial D/PNa-->was higher (0.96) with icodextrin than with the glucose based solutions (0.92), due to the higher Na+ concentration of icodextrin, and it remained unchanged during the dwell. In contrast, D/PNa+ of 1.36% glucose increased during the dwell, whereas D/PNa+ decreased with 3.86% glucose until 60 minutes, followed by a subsequent increase. The ultrafiltration coefficient (UFC) of the total peritoneal membrane was assessed using 3.86% glucose (0.18 +/- 0.04 ml/min/mm Hg), and the UFC of the small pores was assessed using icodextrin (0.06 +/- 0.008 ml/min/mm Hg). The difference between these represented the UFC through the transcellular pores, which averaged 50.5% of the total UFC, but with a very wide range (0 to 85%). An inverse relation existed between the duration of CAPD treatment and the total ultrafiltration coefficient (r = -0.68, P < 0.04), which could be attributed to a lower UFC of the transcellular pores in long-term patients (r = -0.66, P < 0.05), but not to the UFC of the small pores (r = -0.48, NS). The TCUFRo-60 min through the transcellular pores correlated with the sodium gradient, corrected for diffusion, in the first hour of the dwell (r = 0.69, P < 0.04), indicating that both parameters indeed measure transcellular water transport. It can be concluded that the glucose polymer solution induced sustained ultrafiltration and had no effect on peritoneal membrane characteristics. In addition, the results of the present study support the hypothesis that the glucose polymer solutions exerts its osmotic pressure across intercellular pores with radii of about 40 A. This leads to increased clearances of low molecular weight proteins such as beta 2m that are transported through these pores without sieving of Na+. The latter, as found during 3.86% glucose dialysate, is probably caused by transcellular water transport. The transcellular water transport accounted for 50% of the total ultrafiltration with glucose based dialysis solutions. It was lower in long-term CAPD patients.
含有葡萄糖聚合物作为渗透剂的透析液与传统溶液不同,因为它们与血浆等渗,并通过胶体渗透作用产生跨毛细血管超滤(TCUF)。为了研究对液体和溶质动力学的影响,在10例稳定的持续性非卧床腹膜透析(CAPD)患者中,对基于7.5%葡萄糖聚合物的透析液(艾考糊精)与基于1.36%和3.86%葡萄糖的透析液进行了比较。在每位患者中,使用上述渗透剂和浓度进行了三次标准腹膜通透性分析(SPA)。向葡萄糖溶液中添加右旋糖酐70以计算液体动力学。在葡萄糖聚合物SPA中,根据糊精的稀释和消失情况计算液体动力学。艾考糊精的TCUF速率更接近3.86%葡萄糖透析液所获得的速率,而不是1.36%葡萄糖透析液。对液体曲线的外推显示艾考糊精具有持续超滤作用。在艾考糊精试验中,TCUF随时间呈线性增加,而双曲线最能描述葡萄糖曲线。艾考糊精的有效淋巴吸收速率与基于葡萄糖的溶液相似。艾考糊精对低分子量溶质的传质面积系数也与葡萄糖所获得的值相似,肌酐的D/P也是如此。艾考糊精的MTAC肌酐与TCUF速率之间存在正相关(r = 0.66,P = 0.05),而在葡萄糖SPA中不存在这种相关性。这表明在有效腹膜表面积较大的患者中,葡萄糖聚合物溶液可实现更多的超滤。艾考糊精对β2-微球蛋白(β2m)的清除率高于3.86%葡萄糖和1.36%葡萄糖透析液(P < 0.05)。对于较大的血清蛋白白蛋白、IgG和α2-巨球蛋白,未发现差异。由于艾考糊精的Na+浓度较高,艾考糊精的初始D/PNa+较高(0.96),高于基于葡萄糖的溶液(0.92),且在驻留期间保持不变。相比之下,1.36%葡萄糖的D/PNa+在驻留期间增加,而3.86%葡萄糖的D/PNa+在60分钟前降低,随后增加。使用3.86%葡萄糖评估总腹膜膜的超滤系数(UFC)(0.18±0.04 ml/min/mm Hg),使用艾考糊精评估小孔的UFC(0.06±0.008 ml/min/mm Hg)。两者之间的差异代表通过跨细胞孔的UFC,其平均占总UFC的50.5%,但范围非常宽(0至85%)。CAPD治疗时间与总超滤系数之间存在负相关(r = -0.68,P < 0.04),这可能归因于长期患者跨细胞孔的UFC较低(r = -0.66,P < 0.05),但不是小孔的UFC(r = -0.48,无显著性差异)。驻留第一小时通过跨细胞孔的TCUFRo - 60分钟与校正扩散后的钠梯度相关(r = 0.69,P < 0.04),表明这两个参数确实测量了跨细胞水转运。可以得出结论,葡萄糖聚合物溶液可诱导持续超滤,且对腹膜膜特性无影响。此外,本研究结果支持以下假设:葡萄糖聚合物溶液通过半径约为40 Å的细胞间孔施加其渗透压。这导致低分子量蛋白质如β2m的清除率增加,这些蛋白质通过这些孔转运而不被Na+筛分。后者如在3.86%葡萄糖透析液中发现的,可能是由跨细胞水转运引起的。跨细胞水转运占基于葡萄糖的透析溶液总超滤的50%。在长期CAPD患者中较低。